NSE · ORTINGLOBE
Ortin Global Ltd
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹0 Cr with net profit ₹-0 Cr — a -3.23% net margin, versus -500% the period before.
Shareholding
As of 2026-06-30
- Promoter1.23%
- Public96.96%
- FII1.8%
11,383 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #5 of 15 by market cap · medians across 4 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Procter & Gamble Health Limited | ₹10,981 Cr | 116.08 | 20.94 | 62.32% | 23.22% |
| Medico Remedies Limited | ₹384 Cr | 65.15 | 5.06 | 17.38% | 6.36% |
| Par Drugs & Chemicals Ltd. | ₹118 Cr | 138.9 | 1.05 | 11.71% | 12.65% |
| Krebs Biochemicals & Industries Ltd. | ₹117 Cr | — | — | 10.4% | -71.34% |
| Ortin Global Limited(this company) | ₹12 Cr | — | 9.95 | -59.85% | -822.22% |
AI analysis
AI-generated · google/gemini-2.5-flashOrtin Global Limited, incorporated in 1986 and headquartered in Hyderabad, India, operates in the Healthcare sector. The company is involved in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India, offering various pharmaceutical formulations, active pharmaceutical ingredient (API) intermediates, and fine chemicals. It also provides services in process development, analytical research, and diagnostic services. Ortin Global Limited has a market capitalization of Rs 12 Cr.
Positives
- +The company's debt-to-equity ratio is 0.43, indicating a low level of debt.
Negatives
- −The company's Return on Equity (ROE) is -59.85%, indicating significant losses on shareholder funds.
- −The company recorded a negative Return on Capital Employed (ROCE) of -32.1663%, suggesting inefficient use of capital.
- −Ortin Global Limited has a deeply negative profit margin of -822.22% for the reported period.
- −Promoter holding is very low at 1.2335% as of March 31, 2026.
- −The company is under GSM surveillance, indicating potential concerns regarding its financial health or operations.
Business
Ortin Global Limited manufactures and trades pharmaceuticals, drugs, and intermediates. Its product portfolio includes pharmaceutical formulations of tablets, capsules, syrups, and dry powders, covering a wide range of therapeutic areas such as anti-diabetics, anti-allergics, anti-biotics, and anti-retrovirals. The company also offers active pharmaceutical ingredient (API) intermediates and manufactures fine chemicals. Additionally, it provides services in process development, research and development for new formulation brands, and diagnostic services. The company was formerly known as Ortin Laboratories Limited and changed its name in June 2024.
Financial Performance
For the fiscal year ending March 2026, Ortin Global Limited reported a total revenue of Rs 0.31 Cr. The company recorded a net loss of Rs 93,000 in March 2026. The company experienced negative profit margins, with a profit margin of -822.22%. There is no revenue growth figure available.
Profitability & Returns
The company's profitability has been negative, with a Return on Equity (ROE) of -59.85% and a Return on Capital Employed (ROCE) of -32.1663%. For the quarter ending March 2026, the company reported an EPS of -0.01. The comprehensive net profit margin for the period was -822.22%, indicating significant losses relative to revenue.
Balance Sheet
Ortin Global Limited has a book value per share of Rs 1.53. The company's debt-to-equity ratio stands at 0.43, indicating moderate leverage. Further details on the company's assets and liabilities are not available in the provided data.
Ownership & Pledges
As of March 31, 2026, the promoter holding in Ortin Global Limited is 1.2335%. There is no DII holding reported. The company has no promoter shares pledged. The total number of shareholders is 11452.
Regulatory & Surveillance
Ortin Global Limited is currently under surveillance. It has been categorized under the GSM (Graded Surveillance Measure) framework, with a classification of 'GSM 0' and 'GSM'.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.